Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	462 people 2 RCTs in this analysis	At least 1 adverse effect with amisulpride (100–1000 mg/day) with olanzapine (5–20 mg/day) Absolute results not reported	RR 1.03 95% CI 0.87 to 1.21		Not significant
Systematic review	587 people 2 RCTs in this analysis	Extrapyramidal symptoms with amisulpride (100–1000 mg/day) with olanzapine (5–20 mg/day) Absolute results not reported	Reported as not significant P value not reported		Not significant
Systematic review	672 people 3 RCTs in this analysis	Number of people with weight gain with amisulpride (100–1000 mg/day) with olanzapine (5–20 mg/day) Absolute results not reported	RR 0.55 95% CI 0.40 to 0.75	Small effect size	amisulpride
Systematic review	672 people 3 RCTs in this analysis	Weight change from baseline (kg) with amisulpride (100–1000 mg/day) with olanzapine (5–20 mg/day) Absolute results not reported	Difference –2.11 kg 95% CI –2.94 kg to –1.29 kg	Effect size not calculated	amisulpride
Systematic review	303 people 2 RCTs in this analysis	Mean difference in change from baseline in QTc (ms) with amisulpride (100–1000 mg/day) with olanzapine (5–20 mg/day) Absolute results not reported	Mean difference +5.25 ms 95% CI –0.57 ms to +11.07 ms		Not significant
RCT	80 people	Mean weight gain (kg) 12 weeks 3.5 kg with amisulpride (100–800 mg/day) 4.7 kg with olanzapine (10–20 mg/day)	P <0.001	Effect size not calculated	amisulpride
RCT	80 people	Proportion of people with 1 treatment-emergent adverse effect 68% with amisulpride (100–800 mg/day) 48% with olanzapine (10–20 mg/day) Absolute numbers not reported	P = 0.113		Not significant